Atrial Fibrillation News

Atrial fibrillation patients on novel oral anticoagulants (NOACs) don’t need to be managed as closely as patients on warfarin, so it’s widely assumed that bleeding events associated with the newer anticoagulants are more dangerous. However, that might not be the case, according to Blake Charlton,…

By Will Boggs MD NEW YORK (Reuters Health) - Apixaban is safe and effective for anticoagulation in patients with atrial fibrillation (AF) scheduled for cardioversion, according to results from the EMANATE trial. These findings "will allow clinicians to safely cardiovert patients soon after they…

Digoxin use is associated with an increased risk of mortality among patients with atrial fibrillation (AF) with and without heart failure (HF), according to a recent study. For their study, the researchers evaluated 17,987 patients with AF, comparing new digoxin users (n = 5824) with propensity-…

Digoxin serum concentration should be monitored in patients with atrial fibrillation (AF) to ensure blood levels stay below ___________________. a. 1.0 ng/ml b. 1.2 ng/ml c. 1.4 ng/ml d. 1.6 ng/ml To find out the answer, read more. 

What would be the best treatment option for a patient who suffers a major bleeding event while on anticoagulation therapy to treat atrial fibrillation? a. stop anticoagulation therapy b. resume anticoagulation therapy with dabigatran c. resume anticoagulation therapy with warfarin d. resume…

By Scott Baltic NEW YORK (Reuters Health) - In patients with atrial fibrillation (AF) and heart failure with a reduced ejection fraction (HFrEF), beta-blockers are associated with significantly lower all-cause mortality, new research confirms. Hospitalizations and cardiovascular mortality were…

Which anticoagulant carries the lowest risk of metabolic drug-drug interactions? a. warfarin b. rivaroxaban c. apixaban d. dabigatran ----- To see the answer, read more. 

A task force from the American College of Cardiology (ACC) recently published an Expert Consensus Decision Pathway to provide guidance for the periprocedural management of anticoagulation in individuals with nonvalvular atrial fibrillation. Some specific recommendations featured in the Decision…

Cantrell Drug Company is recalling 1494 syringes of Heparin Sodium, 1 USP Unit/2 mL (0.5 USP Units/mL) in 0.45% Sodium Chloride. The US Food and Drug Administration (FDA) Enforcement Report for the week of December 21 lists the reason for the voluntary recall as “lack of assurance of sterility -…

Should the twice-daily dose of the anticoagulant apixaban be reduced from 5 mg to 2.5 mg for an 85-year-old atrial fibrillation patient with renal dysfunction? a. yes b. no ------- To see the answer, read more.